Skip to main content

DNA replication dynamics

Laboratory of Genome Integrity
Junior research group

Every time a cell divides, it must accurately replicate its entire genetic information and ensure its equal distribution between the two daughter cells. To maintain genomic integrity, DNA replication must be both timely and precise. Errors in this process can lead to mutations, which may kill cells, halt their division, or drive uncontrolled proliferation - a hallmark of cancer.

Our research focuses on the mechanisms that regulate DNA replication speed and genome stability. We investigate how cells balance efficient DNA replication with the prevention of harmful replication errors.

A key area of our work is studying PARP inhibitors, a class of chemotherapy drugs used to treat various cancers, including breast, ovarian, prostate, and pancreatic cancers. We have shown that, rather than stalling or collapsing replication forks as previously thought, PARP inhibitors accelerate DNA replication. However, this increase in replication speed comes at a cost: it is associated with the accumulation of single-stranded DNA gaps, which arise when the replication machinery moves too quickly for proper DNA synthesis and repair. These gaps can compromise genome stability and are likely a key factor in the sensitivity of cancer cells to PARP inhibitor treatment.

By uncovering the molecular mechanisms that control DNA replication dynamics and the effects of PARP inhibition, we aim to advance our understanding of genome maintenance and identify new therapeutic strategies to target cancer cells more effectively.

  • DNA replication
  • PARP inhibitors
  • Okazaki fragment processing
  • Replication gap suppression
  • Regulation of replication fork dynamics and its impact on tumorigenesis
  • Beyond catalytic inhibition and trapping: a multi-parameter analysis of PARP inhibitors
  • Single stranded DNA gaps in in early lesions and tumor progression
Emetine blocks DNA replication via proteosynthesis inhibition not by targeting Okazaki fragments. Life Science Alliance. 2022, 5(12), e202201560, ISSN: 2575-1077, PMID: 36260751,
CHROMÁ, K., Z. ŠKROTT, J. GURSKÝ, J. BACOVSKY, P. MOUDRÝ, T. BUCHTOVÁ, M. MISTRÍK, J. BÁRTEK
A drug repurposing strategy for overcoming human multiple myeloma resistance to standard-of-care treatment. Cell Death & Disease. 2022, 13(3), 203, ISSN: 2041-4889, PMID: 35246527,
MOUDRÝ, P., K. CHROMÁ, S. BURSAC, S. VOLAREVIC, J. BÁRTEK
RNA-interference screen for p53 regulators unveils a role of WDR75 in ribosome biogenesis. Cell Death and Differentiation. 2022, 29(3), 687-696, ISSN: 1350-9047, PMID: 34611297,
Project: DNA replication in human pathophysiology
Supervisors: Moudrý Pavel Ph.D.
Available: 1
Intended for: Doctoral training
Summary: 1 full-time position
Project: Cellular stress in health and disease
Supervisors: Mistrík Martin Ph.D., Moudrý Pavel Ph.D., Škrott Zdeněk Ph.D.
Available: 3
Intended for: Doctoral training
BACHELOR STUDENT, IMTM, LIG, MASTER STUDENT
DOCTORAL STUDENT, IMTM, LIG
IMTM, LIG, STAFF
BACHELOR STUDENT, IMTM, LEM, MASTER STUDENT